Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

Inclusion Criteria: 1. ECOG performance status score 0-2; 2. Histologically or cytologically confirmed stage III-IV NSCLC; 3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR/ALK/ROS1/KRAS/MET) should be performed; 4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR/CT for colorectal cancer, and chest CT for breast cancer); 5. No target organ metastasis on baseline imaging (no brain/liver/lung metastasis for lung cancer/colorectal cancer/breast cancer, respectively); 6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up; 7. Regular follow-up during and after treatment; 8. Life expectancy ≥6 months; Exclusion Criteria: 1. Patients with indeterminate pathological type; 2. Patients without baseline imaging data before treatment; 3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer/colorectal cancer/breast cancer corresponding to brain/liver/lung metastasis); 4. patients who cannot or refuse to receive regular imaging follow-up; 5. Combined history of other malignant tumors; 6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; , 7. Lactating or pregnant women; 8. Receiving other long-term medications that may affect disease progression as assessed by a physician.